Domov › Akutna mieločna levkemija › Vermont
Klinične študije za Akutna mieločna levkemija v Vermont
7 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Vermont.
Mesta v Vermont
Uradno besedilo študije (angleško)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Vključevanje udeležencevFaza 2
Starost 18–59 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Vključevanje udeležencevFaza 2
Starost 18–59 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Vermont and State Agricultural College, Burlington
Vključevanje udeležencevFaza 3
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Vermont Medical Center, Burlington
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Vermont, Burlington
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT06001788Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.